In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. (Q38088281)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

In vitro three-dimensional tumor microenvironment models for anticancer drug discovery (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Nikolas K. Haass

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Mercedes Lioni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Kazuhiro Noma

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Meenhard Herlyn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

English

0 references

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

25 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

1-10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23480136%20AND%20SRC:MED&resulttype=core&format=json

A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression

25 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Polarity proteins PAR6 and aPKC regulate cell death through GSK-3beta in 3D epithelial morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Human melanoma progression in skin reconstructs : biological significance of bFGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Adhesion, migration and communication in melanocytes and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Tensional homeostasis and the malignant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

A novel three-dimensional model to quantify metastatic melanoma invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Tumor biology and experimental therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Microenvironmental regulation of proliferation in multicellular spheroids is mediated through differential expression of cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

The role of hypoxia-inducible factor-1 in three-dimensional tumor growth, apoptosis, and regulation by the insulin-signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Towards the targeted therapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Drug resistance and the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Life isn't flat: taking cancer biology to the next dimension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Targeting the stromal fibroblasts: a novel approach to melanoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Tumor-derived lactic acid modulates dendritic cell activation and antigen expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.3.1.1